Researchers at Worrell are seeking adolescents (ages 12 – 17) with the following conditions: neuromyelitis optica spectrum disorder (NMOSD), myasthenia gravis (gMG), myelin oligodendrocyte glycoprotein antibody disease (MOG-AD), or autoimmune encephalitis (AE), to participate in a research study to test the safety and efficacy of a new syringe device being developed to administer a drug to treat the aforementioned conditions. 

This study does not involve an intervention. Enrolled participants will be asked to use a syringe device that will not contain any drug, and will be asked to interact with it and administer a “dose” into a mannequin. The duration of the study will be 60 minutes. 

To be eligible, individuals must meet the following inclusion criteria:

• Adolescent (aged 12 – 17) with the following conditions: NMOSD (Neuromyelitis Optica Spectrum Disorder) gMG (Myasthenia Gravis) MOG-AD (Myelin Oligodendrocyte Glycoprotein Antibody Disease) AE (Autoimmune Encephalitis)
• Current US resident
• Ability to understand instructions in written and spoken English (including being able to read text from a newspaper)
• Willingness and ability to sign an informed consent form
• Consent to digital recordings of the data collection sessions
• Willingness to send a picture of current medication or prescription, in order to be confirmed on the study

Individuals may not be eligible to participate if they meet the following exclusion criteria:

• Unwilling to be video recorded during the study
• Participant, or anyone in household, employed by a medical device manufacturer
• Participant, or anyone in household, employed by a pharmaceutical company
• Participant, or anyone in household, working with a regulatory body such as the FDA or MHRA
• Failure to sign informed consent/authorization before study

Please visit this link for the full listing of inclusion and exclusion criteria.

To inquire about participation, contact the Study Coordinator Matt Hyland by email: mhyland@worrell.com.